In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dyax Corp.

Division of Shire PLC
www.dyax.com

Latest From Dyax Corp.

Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze

With Haegarda holding a convenience edge over Cinryze for HAE prophylaxis, Shire now has data showing that SHP616 also offers significant prevention of HAE attacks. How ‘616 fits into Shire’s overall HAE strategy is unclear.

Life Cycle Management Rare Diseases

Shire CEO Says Lanadelumab Results Vindicate Dyax Buy, M&A Strategy

Shire's CEO is savoring a personal victory after Phase III data for lanadelumab in acute HAE replicated impressive Phase Ib trial results that underpinned his 2015 decision to buy Dyax.

Business Strategies Clinical Trials

Running The Drug Catalyst Gauntlet: What To Look For In Q2 2017

Neurotrope's novel bryostatin treatment for Alzheimer's, AstraZeneca's durvalumab in bladder cancer, and Actelion’s antibiotic cadazolid are among a raft of therapies scheduled for major data read-outs or approval decisions in Q2 2017. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at some crucial drug displays likely over the next three months.

Clinical Trials Cancer

CSL Behring Nears Market With Easier-To-Administer HAE Prophylactic

CSL Behring’s long-acting subcutaneous C1 inhibitor formulation, CSL830, has confirmed its efficacy for the prevention of hereditary angioedema (HAE) attacks, and is expected to be introduced this year, giving it initial traction in what could become a crowded sector.

Clinical Trials Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Shire PLC
  • Senior Management
  • Gustav A Christensen, Pres. & CEO
    George Migausky, EVP, CFO
    Burt Adelman , MD, EVP, R&D & CMO
    Todd Bazemore, EVP, Chief Commercial Officer
  • Contact Info
  • Dyax Corp.
    Phone: (617) 225-2500
    55 Network Dr.
    Burlington, MA 01803
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register